SK137797A3 - Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells - Google Patents

Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells Download PDF

Info

Publication number
SK137797A3
SK137797A3 SK1377-97A SK137797A SK137797A3 SK 137797 A3 SK137797 A3 SK 137797A3 SK 137797 A SK137797 A SK 137797A SK 137797 A3 SK137797 A3 SK 137797A3
Authority
SK
Slovakia
Prior art keywords
virus according
sequence
promoter
expression signal
virus
Prior art date
Application number
SK1377-97A
Other languages
English (en)
Slovak (sk)
Inventor
Ruihuan Chen
Bruno Doiron
Axel Kahn
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of SK137797A3 publication Critical patent/SK137797A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1377-97A 1995-04-14 1996-04-12 Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells SK137797A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504558A FR2732978B1 (fr) 1995-04-14 1995-04-14 Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
PCT/FR1996/000560 WO1996032489A1 (fr) 1995-04-14 1996-04-12 Vecteur viral recombinant inductible par le glucose

Publications (1)

Publication Number Publication Date
SK137797A3 true SK137797A3 (en) 1998-05-06

Family

ID=9478162

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1377-97A SK137797A3 (en) 1995-04-14 1996-04-12 Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells

Country Status (14)

Country Link
US (1) US6309878B1 (fr)
EP (1) EP0821741A1 (fr)
JP (1) JPH11503608A (fr)
KR (1) KR19980703843A (fr)
AU (1) AU715377B2 (fr)
BR (1) BR9604938A (fr)
CA (1) CA2215987A1 (fr)
CZ (1) CZ292564B6 (fr)
FR (1) FR2732978B1 (fr)
HU (1) HUP9802587A3 (fr)
MX (1) MX9707910A (fr)
NO (1) NO974726L (fr)
SK (1) SK137797A3 (fr)
WO (1) WO1996032489A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5257198A (en) * 1996-11-15 1998-06-03 Millennium Pharmaceuticals, Inc. Compositions and methods for treating type ii diabetes involving hnf-4
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
EP1889914A1 (fr) * 1999-02-19 2008-02-20 Engene, Inc. Compositions de thérapie génétique pour le diabète
US6503887B1 (en) 1999-02-19 2003-01-07 Matthew During Peroral gene therapy of diabetes and obesity
JP3406244B2 (ja) 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
EP1199720A4 (fr) 1999-05-27 2008-01-23 Hitachi Global Storage Tech Lecteur de disque
WO2002089855A1 (fr) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Transduction perorale d'hepatocytes dans le traitement d'une maladie
DE102005024884A1 (de) * 2005-05-31 2006-12-07 Linde Ag Arbeitsmaschine, insbesondere Flurförderzeug
EP1890708A4 (fr) * 2005-06-01 2009-07-15 Biotec Inst For Internat Expression d'insuline inductible par glucose et methodes de traitement du diabete
ES2325711B1 (es) * 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0588914A1 (fr) * 1991-05-29 1994-03-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vecteurs d'expression eukariotique a regulation du traitement d'arn
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
CA2166078A1 (fr) * 1993-06-28 1995-01-05 Christopher B. Newgard Vecteurs pour cellules concues genetiquement, produisant de l'insuline en reponse au glucose

Also Published As

Publication number Publication date
FR2732978B1 (fr) 1997-05-30
CZ292564B6 (cs) 2003-10-15
WO1996032489A1 (fr) 1996-10-17
JPH11503608A (ja) 1999-03-30
FR2732978A1 (fr) 1996-10-18
EP0821741A1 (fr) 1998-02-04
AU5652396A (en) 1996-10-30
HUP9802587A2 (hu) 1999-02-01
NO974726D0 (no) 1997-10-13
HUP9802587A3 (en) 1999-12-28
KR19980703843A (ko) 1998-12-05
CZ325197A3 (cs) 1998-01-14
MX9707910A (es) 1997-11-29
CA2215987A1 (fr) 1996-10-17
US6309878B1 (en) 2001-10-30
NO974726L (no) 1997-10-13
BR9604938A (pt) 1998-06-09
AU715377B2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
CA2229631C (fr) Therapie genique utilisant des vecteurs d'adenovirus ovins
JP5823969B2 (ja) 心臓特異的核酸調節因子ならびにこの方法および使用
WO1998032869A1 (fr) Vecteurs d'expression et procedes d'expression in vivo de polypeptides therapeutiques
JPH10507061A (ja) アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
US20050260164A1 (en) Gene regulation with aptamer and modulator complexes for gene therapy
US20020123146A1 (en) Highly productive packaging lines
US6806080B2 (en) Hybrid vectors for gene therapy
SK137797A3 (en) Recombinant viral vector, pharmaceutical composition containing the same and corresponding transformed cells
KR100246096B1 (ko) 유전자 요법을 위한 개선된 레트로바이러스 벡터
CN115803441A (zh) 用于恢复pah基因功能的腺相关病毒组合物和其使用方法
JPH11514881A (ja) Ｇａｘタンパク質の癌治療への応用
JP2001503279A (ja) ターゲットを定めて遺伝子を誘導発現させるための新規な構築物及びベクター
CN114934070A (zh) 间充质干细胞及其抗炎应用
WO1999051755A2 (fr) Regulation a mediation par ribozymes de l'expression de genes
US20020028212A1 (en) Recombinant viruses coding for a glutamate decarboxylase (gad) activity
AU766153B2 (en) Use of negative regulation elements for nerve-specific expression of transgenes
Rasmussen et al. Complementarity between RNA dimerization elements favors formation of functional heterozygous murine leukemia viruses
KR20000010608A (ko) 티로신 하이드록실라제 유전자로부터 유도된 발현 시스템
US20060233757A1 (en) Vectors with viral insulators
WO2022234051A1 (fr) Enzyme d'édition primaire divisée
JP2002291492A (ja) ペプチドベクター
MXPA00007617A (en) Use of negative regulation elements for nerve-specific expression of transgenes
WO2001025452A1 (fr) Therapie genique ciblee
AU4233499A (en) Recombinant viruses coding for a glutamate decarboxylase (GAD) activity
AU2928402A (en) Recombinant viruses coding for a glutamate decarboxylase (GAD) activity